Neuralstem (NASDAQ: CUR) and Opko Health (NASDAQ:OPK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.
This table compares Neuralstem and Opko Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Neuralstem has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Opko Health has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Neuralstem and Opko Health, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Neuralstem currently has a consensus target price of $3.18, indicating a potential upside of 189.09%. Opko Health has a consensus target price of $14.81, indicating a potential upside of 195.66%. Given Opko Health’s higher probable upside, analysts plainly believe Opko Health is more favorable than Neuralstem.
Institutional & Insider Ownership
5.8% of Neuralstem shares are held by institutional investors. Comparatively, 22.3% of Opko Health shares are held by institutional investors. 19.3% of Neuralstem shares are held by insiders. Comparatively, 40.2% of Opko Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Neuralstem and Opko Health’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Opko Health||$1.22 billion||2.29||-$25.08 million||($0.22)||-22.77|
Neuralstem has higher revenue, but lower earnings than Opko Health.
Opko Health beats Neuralstem on 9 of the 11 factors compared between the two stocks.
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.
About Opko Health
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.